Delcath Systems Stock Forecast, Price & News

+0.32 (+3.24 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume25,825 shs
Average Volume56,527 shs
Market Capitalization$71.60 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DCTH News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Delcath Systems logo

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.33 out of 5 stars

Medical Sector

113th out of 842 stocks

Surgical & Medical Instruments Industry

11th out of 74 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Delcath Systems (NASDAQ:DCTH) Frequently Asked Questions

Is Delcath Systems a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Delcath Systems stock.
View analyst ratings for Delcath Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Delcath Systems?

Wall Street analysts have given Delcath Systems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Delcath Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Delcath Systems' next earnings date?

Delcath Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Delcath Systems

How can I listen to Delcath Systems' earnings call?

Delcath Systems will be holding an earnings conference call on Tuesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) announced its earnings results on Tuesday, May, 11th. The company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.15. The business earned $0.39 million during the quarter, compared to analyst estimates of $0.38 million. Delcath Systems had a negative net margin of 1,551.65% and a negative trailing twelve-month return on equity of 173.70%.
View Delcath Systems' earnings history

How has Delcath Systems' stock price been impacted by Coronavirus (COVID-19)?

Delcath Systems' stock was trading at $9.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DCTH stock has increased by 10.9% and is now trading at $10.20.
View which stocks have been most impacted by COVID-19

When did Delcath Systems' stock split? How did Delcath Systems' stock split work?

Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of Delcath Systems stock prior to the reverse split would have 1 shares after the split.

What price target have analysts set for DCTH?

3 brokerages have issued 12-month target prices for Delcath Systems' shares. Their forecasts range from $23.00 to $25.00. On average, they anticipate Delcath Systems' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts' price targets for Delcath Systems
or view top-rated stocks among Wall Street analysts.

Who are Delcath Systems' key executives?

Delcath Systems' management team includes the following people:
  • Mr. Gerard J. Michel, CEO & Director (Age 58, Pay $132k)
  • Mr. John Purpura M.S., Chief Operating Officer (Age 60, Pay $437.37k)
  • Ms. Christine Padula, Interim Principal Accounting Officer (Age 56, Pay $200.3k)
  • Mr. Thomas Johnson, Sr. Director of Corp. Communications
  • Mr. Robin Wagge, Sr. VP of Rubenstein Associates
  • Dr. Johnny John M.D., Sr. VP Clinical Devel. & Medical Affairs

Who are some of Delcath Systems' key competitors?

What is Delcath Systems' stock symbol?

Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH."

How do I buy shares of Delcath Systems?

Shares of DCTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Delcath Systems' stock price today?

One share of DCTH stock can currently be purchased for approximately $10.20.

How much money does Delcath Systems make?

Delcath Systems has a market capitalization of $71.60 million and generates $1.16 million in revenue each year. The company earns $-24,160,000.00 in net income (profit) each year or ($8.35) on an earnings per share basis.

How many employees does Delcath Systems have?

Delcath Systems employs 36 workers across the globe.

What is Delcath Systems' official website?

The official website for Delcath Systems is

Where are Delcath Systems' headquarters?

Delcath Systems is headquartered at 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019.

How can I contact Delcath Systems?

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The company can be reached via phone at 212 489 2100 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.